The FDA announced on October 20, 2026, that it had approved the first generic hormone therapy patch equivalent to Climara Pro. Approved the previous day, the once-weekly estradiol and levonorgestrel transdermal system is intended for women with an intact uterus. Its approved uses are treatment of moderate to severe vasomotor symptoms due to menopause and prevention of postmenopausal osteoporosis.
The approval went to Zydus Pharmaceuticals (USA) Inc. In its announcement about the first generic Climara Pro patch, FDA described the product as therapeutically equivalent to the brand-name medicine. The announcement did not provide a price or a date when pharmacies would begin stocking it.
What the generic hormone therapy patch is approved for
The patch delivers two hormones through the skin: estradiol, an estrogen, and levonorgestrel, a progestogen. It is applied once a week rather than taken as a daily oral medication.
FDA lists two approved uses for women with an intact uterus:
- Treatment of moderate to severe vasomotor symptoms due to menopause.
- Prevention of osteoporosis after menopause.
These indications define the scope of the approval. The osteoporosis indication is for prevention; the announcement does not describe an approval to treat established osteoporosis. Nor does it establish this combination patch as appropriate for every woman experiencing menopause.
Why the two-hormone combination matters
Unlike estrogen-only patches commonly used in menopause treatment, Climara Pro and its generic contain both estrogen and progestogen in a single patch. FDA explains that the progestogen component reduces the risk of endometrial hyperplasia, or overgrowth of the uterine lining, that can occur with estrogen alone.
This distinction is central to the product’s approval for women who still have a uterus. Readers exploring the broader subject can also review this overview of hormone replacement therapy; the specific uses and restrictions for this newly approved patch remain important to any discussion with a healthcare professional.
Important safety restrictions and side effects
A generic approval does not remove the medicine’s safety restrictions. FDA lists the same contraindications—conditions in which the medicine should not be used—for Climara Pro and the generic patch. These include:
- Undiagnosed abnormal genital bleeding.
- Breast cancer or a history of breast cancer, and estrogen-dependent tumors.
- Active deep vein thrombosis or pulmonary embolism, or a history of either condition.
- Active arterial thromboembolic disease or a history of these conditions.
- Known anaphylactic reaction, angioedema, or hypersensitivity to estradiol and levonorgestrel.
- Liver impairment or disease.
- Protein C, protein S, or antithrombin deficiency, or other thrombophilic disorders.
The most common adverse reactions, reported at a frequency of at least 5%, include application-site reactions, vaginal bleeding, breast pain, upper respiratory infection, back pain, depression, pain, headache, and flu syndrome.
These restrictions make a discussion of medical history with a healthcare professional important before considering the patch. Questions about unexplained bleeding, previous blood clots, cancer history, liver disease, allergic reactions, or possible side effects require professional medical advice rather than a decision based solely on the approval announcement.
What the approval means for access
FDA framed the approval as a step toward expanding access to affordable medicines. The agency explained that additional generic medicines can create market competition, which can help make treatment more affordable. However, it did not announce a specific savings amount, retail price, or insurance coverage for this product.
The once-weekly format offers an alternative to daily oral medications. FDA said that convenience may help patients stay on track with treatment, but it did not report a guaranteed adherence benefit. For information about when the medicine will be available, the agency directed readers to the manufacturer.
Frequently Asked Questions
Is this an estrogen-only patch?
No. It contains estradiol and levonorgestrel, combining estrogen and progestogen in one once-weekly patch.
Who is the patch approved for?
It is specifically approved for women with an intact uterus to treat moderate to severe menopausal vasomotor symptoms or prevent postmenopausal osteoporosis, subject to its safety restrictions.
Is the generic available now, and what will it cost?
The FDA announcement did not specify a launch date or price. It directed readers to the manufacturer for availability information.
